Urinary proteomic panels, notably the CE-MS derived CKD273 classifier, are gaining traction as early, mechanism-informed predictors of diabetic kidney disease (DKD) progression and may reshape referral pathways for people with type 2 diabetes (T2D). Multiple longitudinal and validation studies show that CKD273 identifies patients at elevated risk of developing albuminuria or progressive loss of glomerular filtration before conventional markers become abnormal: the prospective PRIORITY study demonstrated that a high CKD273 score in normoalbuminuric T2D participants predicted new-onset microalbuminuria independent of standard clinical risk factors, establishing clinical prognostic value for earlier disease detection.
3 Meta-analyses and subsequent cohort work reinforce that CKD273 improves discrimination over albuminuria alone and correlates with harder renal endpoints and adverse…
